Bhubaneswar-based healthcare startup CureBay has raised ₹100 crore in a pre-Series C round led by IvyCap Ventures. The capital, comprising ₹69 crore in equity and ₹30 crore in debt, will fuel expansion into Andhra Pradesh and enhance AI-based diagnostic tools. Investors will now watch how the company balances its rapid physical clinic expansion with the need to manage debt obligations and ensure operational efficiency in remote areas.
CureBay, a healthcare startup focused on rural areas, has secured ₹100 crore in a pre-Series C funding round. The investment was led by IvyCap Ventures, which provided ₹69 crore in equity. Additional funding included ₹30 crore in debt from lenders such as Trifecta Capital, Alteria Capital, and VentureSoul Partners. The company plans to use these funds to increase its reach, with a primary focus on entering the Andhra Pradesh market, and to upgrade its technology stack.
The startup operates a hub-and-spoke model, which aims to bring primary healthcare services to underserved regions. Currently, CureBay manages over 250 tech-enabled clinics across seven states, including Odisha, Bihar, and Jharkhand. Its model relies on a mix of community health workers, known as Swasthya Mitras, and remote doctors who provide video consultations. The company reports that it has served over 1.7 million patients since its inception in 2021.
A significant portion of the new capital is earmarked for the company's proprietary intelligence layer. The firm is investing in GPU infrastructure to train AI models that assist with patient screening and clinical decision support, specifically in dermatology and dental care. By automating routine assessments, the company intends to reduce the workload for its 530-member clinical staff and network of over 230 partner doctors.
While the company is scaling up, the inclusion of debt in its funding mix brings specific financial pressure. Startups that rely on debt financing must ensure consistent cash flow to meet interest payments, especially as they scale operations into new territories like Andhra Pradesh. Successfully managing these costs while maintaining service quality in remote rural locations remains a key operational challenge. Additionally, the company must ensure that its AI-driven diagnostic tools meet strict accuracy and data privacy standards as it integrates them into clinical workflows.
For investors and stakeholders, the next phase will be about measuring how effectively the company executes its expansion plans. Monitoring the pace of new clinic openings, the actual adoption of the new AI diagnostic tools by its staff, and the company's ability to maintain healthy margins while servicing its new debt will be important. Furthermore, the company's role in government initiatives like the Samriddhi Kendra, which uses BharatNet broadband for remote services, will remain a key monitorable to gauge its long-term growth and stability in the competitive Indian healthtech sector.